Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenotypic reversion in acute promyelocytic leukemia.

L Degos1

  • 1INSERM U 93, Centre Hayem, Hôpital Saint-Louis, Paris, France.

Nouvelle Revue Francaise D'Hematologie
|January 1, 1991
PubMed
Summary

Acute promyelocytic leukemia (APL) treatment with all-trans retinoic acid effectively induces remission by promoting cancer cell maturation. This differentiation therapy targets the molecular mechanisms underlying APL leukemogenesis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Confronted to medical error, emphasize its positive aspects].

La Revue de medecine interne·2014
Same author

Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients.

Leukemia·2014
Same author

[Developing health services research in France, one of the HAS missions].

Revue d'epidemiologie et de sante publique·2008
Same author

Treatment of acute promyelocytic leukemia by retinoids.

Current topics in microbiology and immunology·2007
Same author

Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).

Leukemia·2006
Same author

Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Leukemia·2005

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute promyelocytic leukemia (APL) is characterized by malignant myeloid cell proliferation and a significant risk of fatal hemorrhage.
  • The t(15;17) translocation is a hallmark of APL, leading to a bleeding diathesis linked to disseminated intravascular coagulation and primary fibrinolysis.
  • Early mortality in APL, around 20%, is primarily attributed to the severe hemorrhagic syndrome.

Purpose of the Study:

  • To investigate the efficacy of all-trans retinoic acid (ATRA) in inducing remission in APL patients.
  • To explore the molecular mechanisms of ATRA's differentiation therapy.
  • To understand the role of the retinoic acid receptor alpha (RARα) gene in APL leukemogenesis.

Main Methods:

  • Clinical observation of patient responses to ATRA treatment.
  • Molecular studies analyzing the t(15;17) translocation breakpoints within the RARα gene.
  • Gene transfection experiments to assess the functional impact of hybrid gene products.

Main Results:

  • All-trans retinoic acid demonstrates high effectiveness in inducing complete remission in APL patients.
  • ATRA functions as a differentiation therapy by inducing cellular maturation.
  • The t(15;17) translocation generates a hybrid RARα gene product that impairs gene transactivation, offering insights into leukemogenesis.

Conclusions:

  • ATRA represents a groundbreaking differentiation therapy for APL, significantly improving patient outcomes.
  • Pharmacological concentrations of retinoic acid can overcome the abnormal program caused by the aberrant transcript.
  • Understanding the molecular basis of APL, particularly the RARα gene's role, opens new therapeutic avenues.

Related Experiment Videos